During the last session, Iterum Therapeutics plc (NASDAQ:ITRM)’s traded shares were 14,485,109, with the beta value of the company hitting 0. At the end of the trading day, the stock’s price was $1.57, reflecting an intraday gain of 0.64% or $0.01. The 52-week high for the ITRM share is $6.02, that puts it down -283.44% from that peak though still a striking +71.27% gain since the share price plummeted to a 52-week low of $0.451. The company’s market capitalization is $277.07 Million, and the average intraday trading volume over the past 10 days was 8.47 Million shares, and the average trade volume was 26.75 Million shares over the past three months.
Iterum Therapeutics plc (ITRM) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 3. ITRM has a Sell rating from 1 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 1 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.07.
Iterum Therapeutics plc (NASDAQ:ITRM): Trading Information
Iterum Therapeutics plc (ITRM) registered a 0.64% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.85% in intraday trading to $1.65 this Wednesday, Apr 07, hitting a weekly high. The stock’s 5-day price performance is 10.56%, and it has moved by 3.97% in 30 days. Based on these gigs, the overall price performance for the year is 58.75%. The short interest in Iterum Therapeutics plc (NASDAQ:ITRM) is 5.27 Million shares and it means that shorts have 0.2 day(s) to cover.
The consensus price target of analysts on Wall Street is $2.25, which implies an increase of 43.31% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $2.5 respectively. As a result, ITRM is trading at a discount of 59.24% off the target high and 27.39% off the low.
Iterum Therapeutics plc (ITRM) projections and forecasts
An analysis of the company’s performance over the past 5 years shows that the company’s earnings fell an estimated 0%. While earnings are projected to return 69.5% in 2021, the next five years will return 0% per annum.
Iterum Therapeutics plc (NASDAQ:ITRM)’s Biggest Investors
Iterum Therapeutics plc insiders own 0.61% of total outstanding shares while institutional holders control 9.16%, with the float percentage being 9.22%. Canaan Partners X LLC is the largest shareholder of the company, while 28 institutions own stock in it. As of Dec 30, 2020, the company held over 1.73 Million shares (or 0.98% of all shares), a total value of $1.71 Million in shares.
The next largest institutional holding, with 1.54 Million shares, is of Frazier Management LLC’s that is approximately 0.87% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $1.52 Million.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.